EN | RU
EN | RU

Help Support

Back

Study determines long-term efficacy and safety of upadacitinib in atopic dermatitis

Atopic_dermatitis Atopic_dermatitis
Atopic_dermatitis Atopic_dermatitis

What's new?

Continuous upadacitinib therapy was well-tolerated and exhibited a favorable longer-term benefit-risk profile in people having atopic dermatitis.

In an assessment of follow-up data from two ongoing phase 3 trials (Measure Up 1 and Measure Up 2), longer-term upadacitinib therapy showed a promising benefit-risk profile, with sustained effectiveness responses through fifty-two weeks in atopic dermatitis people. This study aimed to assess whether upadacitinib's safety and effectiveness is maintained through fifty-two weeks of continuous therapy in adults and adolescents suffering from moderate to severe atopic dermatitis

Participants were randomly allocated to get once-daily oral upadacitinib 15 mg, 30 mg, or placebo.

At 16th week, subjects randomized at baseline to get 15 mg upadacitinib (273 subjects in Measure Up 1 and 260 subjects in Measure Up 2) and 30 mg (270 subjects in Measure Up 1 and 268 subjects in Measure Up 2) continued the assigned therapy. In a double-blinded manner, the placebo-treated people were rerandomized to get 15 mg upadacitinib (121 subjects in Measure Up 1 and 120 subjects in Measure Up 2) or 30 mg (123 subjects in Measure Up 1 and 121 subjects in Measure Up 2).

Assessment of safety and effectiveness including Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score and 75% improvement in Eczema Area and Severity Index (EASI) was done. Measure Up 1 and Measure Up 2 incorporated 1609 volunteers (727 females; 882 males; mean age 33.8 years). The effectiveness at week 16 was maintained through week fifty-two.

At week fifty-two, the percentage of people who experienced 75% improvement in EASI and who attained vIGA-AD score of clear (0) or almost clear (1) with 2 or higher grades of improvement with the 15-mg dose and 30-mg upadacitinib dose in Measure Up 1 and Measure Up 2, are shown in Table 1.

Treatment discontinuation due to adverse events was found to be low overall. However, it was slightly higher for the 30-mg upadacitinib dose. Both the doses of upadacitinib showed good tolerability with no novel safety signals. Thus, the findings through fifty-two weeks illustrated  maintenance of efficacy and acceptable longer-term safety of upadacitinib monotherapy for atopic dermatitis management.

Source:

JAMA Dermatology

Article:

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials

Authors:

Eric L Simpson et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: